eptacog beta at a glance
Medicine class
Recombinant activated factor VII bypassing agent
Licensed age group
Adults and adolescents aged 12 years and older
Administration
Intravenous injection after reconstitution; home use requires specialist training
What is eptacog beta used for?
Licensed uses in people aged 12 years and older with congenital haemophilia A or B and specified factor VIII or IX inhibitors include:
Treating bleeding episodes.
Preventing and managing bleeding during surgery or invasive procedures.
Use with high-responding inhibitors, or selected low-titre inhibitors expected to respond strongly again or be refractory to increased factor VIII or IX replacement.
How does eptacog beta work?
Eptacog beta activates factor X and supports thrombin and fibrin formation at the bleeding site. This bypasses factor VIII or IX when inhibitors make conventional replacement factors ineffective.
eptacog beta preparations and strengths
Injection
Route: Parenteral
Strengths: 1 mg, 2 mg, 5 mg
How to take eptacog beta
Treatment must be initiated and supervised by a clinician experienced in haemophilia or bleeding disorders.
Reconstitute the powder only with the supplied water for injections, using aseptic technique.
Inject into a vein only; do not inject under the skin or into a muscle.
Self-inject only after training from the haemophilia treatment centre.
Do not mix the prepared solution with other medicines.
Record the product name and batch number after each administration.
eptacog beta side effects
Common or expected effects
- Dizziness or headache
- Injection-site discomfort or bruising
- Injection-related reaction
- Raised body temperature
- Bruising after a procedure
Get urgent medical advice
- Severe allergic or anaphylactic reaction
- Arterial or venous blood clot
- Unexpected loss of bleeding control, which may indicate neutralising antibodies
eptacog beta in pregnancy
There are no adequate data from pregnant women. Use is preferably avoided unless a specialist considers treatment necessary after assessing maternal and fetal benefits and risks.
eptacog beta while breastfeeding
It is unknown whether eptacog beta passes into human milk or affects milk production. A specialist should weigh the benefit of breastfeeding against the clinical need for treatment.
eptacog beta interactions
Formal interaction studies have not been conducted. Important haemostatic combinations require specialist oversight.
Activated prothrombin complex concentrate
Simultaneous use may increase the risk of thromboembolic events.
Other activated factor VII products or prothrombin complex concentrates
Combined procoagulant effects may increase clotting risk.
Factor XIII
Combining recombinant factor VIIa with factor XIII is not recommended because clinical interaction data are unavailable and non-clinical evidence raises concern.
Common questions about eptacog beta
Answers are fully visible for fast scanning and source review.
Why is eptacog beta called a bypassing agent?
It activates clotting downstream of factor VIII and IX, bypassing those factors when they are absent, ineffective or blocked by inhibitors.
Who is eptacog beta licensed for?
Adults and adolescents aged 12 years and older with congenital haemophilia A or B and specified factor VIII or IX inhibitors.
Can it be used during surgery?
Yes. Its licence includes preventing and managing bleeding during surgery or invasive procedures in the indicated inhibitor population.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.